Insights

Pipeline Support Armis is developing non systemic anti infective treatments for antibiotic resistance and healthcare associated infections. Business development teams can explore partnerships, research services, clinical development support, and access to healthcare or pharmaceutical networks.

Defense Opportunity The company is developing a chemical wound treatment for the US market, while Veriox is described as active against diverse biological threats. This may create opportunities with government, defense, emergency response, and wound care organizations seeking infection control solutions.

Product Expansion Armis has launched products spanning surface disinfection, hand hygiene, animal wound care, and oral device cleansing. Distributors, healthcare procurement teams, veterinary channels, and manufacturers of medical devices could be relevant prospects for sales or commercialization partnerships.

Lean Operations With 2 to 10 employees and reported revenue below $1 million, Armis may benefit from outsourced capabilities such as contract manufacturing, regulatory support, commercialization, and channel distribution. Prospects should qualify budget, product readiness, and partnership priorities before pursuing.

Leadership Transition Michael Voss became CEO in July 2024, succeeding Ted Ziemann. This leadership change can be a timely opening for business development outreach focused on growth priorities, strategic partnerships, and scaling the company’s product portfolio.

Similar companies to Armis Biopharma

Armis Biopharma Tech Stack

Armis Biopharma uses 8 technology products and services including iCIMS, Amazon Web Services, WordPress, and more. Explore Armis Biopharma's tech stack below.

Armis Biopharma's Email Address Formats

Armis Biopharma uses at least 1 email format:
Armis Biopharma Email FormatsExamplePercentage
First.Last@armisbiopharma.comJohn.Doe@armisbiopharma.com
100%

Frequently Asked Questions

What is Armis Biopharma's official website and social media links?

Minus sign iconPlus sign icon
Armis Biopharma's official website is armisbiopharma.com and has social profiles on LinkedIn.

How much revenue does Armis Biopharma generate?

Minus sign iconPlus sign icon
As of July 2026, Armis Biopharma's annual revenue is estimated to be <$1M.

What is Armis Biopharma's SIC code and NAICS code?

Minus sign iconPlus sign icon
Armis Biopharma's SIC code is 8733 - Noncommercial Research Organizations and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Armis Biopharma have currently?

Minus sign iconPlus sign icon
As of July 2026, Armis Biopharma has approximately 6 employees across 1 continents, including North America. Key team members include Vice-President: F. O., Director Of Business And Corporate Development: A. P. and Principal: L. G. Explore Armis Biopharma's employee directory with LeadIQ.

What industry does Armis Biopharma belong to?

Minus sign iconPlus sign icon
Armis Biopharma operates in the Biotechnology industry.

What technology does Armis Biopharma use?

Minus sign iconPlus sign icon
Armis Biopharma's tech stack includes iCIMS, Amazon Web Services, WordPress, Shopify, Google Cloud, PayPal, Venmo and Piwik PRO Core.

What is Armis Biopharma's email format?

Minus sign iconPlus sign icon
Armis Biopharma's email format typically follows the pattern of First.Last@armisbiopharma.com. Find more Armis Biopharma email formats with LeadIQ.

When was Armis Biopharma founded?

Minus sign iconPlus sign icon
Armis Biopharma was founded in 2017.
Armis Biopharma logo

Armis Biopharma

BiotechnologyColorado, United States2-10 Employees

Armis Biopharma, Inc. is a Fort Collins, Colorado-based biotechnology research company focused on developing non-systemic anti-infective therapies aimed at countering antibiotic resistance and healthcare-associated infections. The organization maintains a growing pipeline of targeted antimicrobial treatments intended for use in healthcare settings to reduce infection-related harm. Its mission centers on decreasing the incidence and severity of infections that cause human suffering and death through new antimicrobial modalities.

The lead technology, Veriox, relies on a novel mechanism of action designed to be effective against a broad range of pathogens, including Gram-positive and Gram-negative bacteria, viruses, fungi, spores, and chemical/biological warfare pathogens, while aiming to minimize systemic toxicity. The company’s target customers are healthcare providers and institutions seeking therapies that mitigate resistant infections and related complications. In July 2024, Armis Biopharma appointed Michael Voss as chief executive officer, succeeding Ted Ziemann, who retired after six years at the helm.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
2-10

Section iconFunding & Financials

  • <$1M

    Armis Biopharma's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.